In the DMBC22 cell line, treatment with the tested compound at 0.4 μM in culture medium for 72 h markedly reduced viability by 52%, as evidenced by changes in acid phosphatase activity. DMBC11 cells were exposed to 0.4 μM 17-aminogeldanamycin (AG) for 22 h. CCND1 mRNA level was further reduced to about 50% of control. In fixed ACE2 cerulean cells, the tested compound was incubated with S1-OFP before treatment of the cells. Inhibition of fluorescent spike protein binding to hACE2 cerulean was observed compared with DMSO control. In DMBC21 cells, treatment with the study compound at 0.4 μM in culture medium for 72 h further increased the percentages of cells with active caspase-3/7 up to 30–35% and was associated with cell detachment, compared with GEL at the same concentration. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Reduced Viability in the DMBC22 Cell Line
Cell-based study · DMBC22 cell line [1]
In the DMBC22 cell line, treatment with the tested compound at 0.4 μM in culture medium for 72 h markedly reduced viability by 52%, as evidenced by changes in acid phosphatase activity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.4 μM
- Exposure duration
- 72 h
- Method
- drugs were dissolved in the culture medium
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: IPI-493; Compound label in the paper: 17-Aminogeldanamycin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Drugs (S12, S13); Results > AG is also effective against NRASQ61R melanoma cells (S95, S96, S106)
viability in DMBC22 cell line: viability in DMBC22 cell line; comparator: control — Results > AG is also effective against NRASQ61R melanoma cells (S96)
Reduced CCND1 mRNA in DMBC11 Cells
Cell-based study · DMBC11 [2]
DMBC11 cells were exposed to 0.4 μM 17-aminogeldanamycin (AG) for 22 h. CCND1 mRNA level was further reduced to about 50% of control.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.4 μM
- Exposure duration
- 22 h
- Method
- exposed to 0.4 μM 17-aminogeldanamycin (AG)
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: IPI-493; Compound label in the paper: 17-Aminogeldanamycin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Results > 2.4. AG Diversely Affects Transcript and Proteins Levels of Different NF-κB-Dependent Genes (S35, S36, S37); 4. Materials and Methods > 4.1. Cell Culture (S51, S54); Figure 4 legend (S145)
CCND1 mRNA level: CCND1 mRNA level; comparator: control — 2. Results > 2.4. AG Diversely Affects Transcript and Proteins Levels of Different NF-κB-Dependent Genes (S37)
Fluorescent spike protein binding inhibition in fixed cells
Cell-based study · fixed ACE2 cerulean cells [3]
In fixed ACE2 cerulean cells, the tested compound was incubated with S1-OFP before treatment of the cells. Inhibition of fluorescent spike protein binding to hACE2 cerulean was observed compared with DMSO control.
Literature-Reported Treatment Conditions
- Exposure duration
- for 15 min
- Method
- incubated with S1-OFP for 1 h and further treated with fixed ACE2 cerulean cells
- Vehicle
- DMSO
- Co-treatment
- Other interventions in this design: S1-OFP. Compound effect isolated by the comparison: when compared with DMSO control.
- Reported limits
- Not stated in the sentences used: dose.
Methods and source locations
Compound reported in the paper: IPI-493; Compound label in the paper: 17-Aminodemethoxygeldanamycin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > ACE2– spike S1- binding study (S71, S73); Results > ACE2-S1-binding assay (S136, S137, S138)
binding of fluorescent spike protein to hACE2 cerulean: binding of fluorescent spike protein to hACE2 cerulean; comparator: DMSO control — Results > ACE2-S1-binding assay (S136, S138)
Increased active caspase percentages and cell detachment
Cell-based study · DMBC21 [1]
In DMBC21 cells, treatment with the study compound at 0.4 μM in culture medium for 72 h further increased the percentages of cells with active caspase-3/7 up to 30–35% and was associated with cell detachment, compared with GEL at the same concentration.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.4 μM
- Exposure duration
- 72 h
- Method
- drugs were dissolved in the culture medium
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: IPI-493; Compound label in the paper: 17-Aminogeldanamycin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Drugs (S12, S13); Materials and methods > A time-lapse fluorescent microscopy (S18); Results > 17-Aminogeldanamycin (AG) is more effective than geldanamycin (GEL) in caspase-3/7 activation in melanoma cells (S44, S45, S46); Fig. 1 legend (S112)
Percentages of cells with active caspase-3/7: Percentages of cells with active caspase-3/7; comparator: GEL at this concentration — Results > 17-Aminogeldanamycin (AG) is more effective than geldanamycin (GEL) in caspase-3/7 activation in melanoma cells (S46); Fig. 1 legend (S112)